Amid the geopolitical turbulence, a piece of welcome news emerged from the world of medicine. Pfizer announced that its experimental breast cancer drug, atirmociclib, significantly reduced the risk of disease progression in a mid-stage clinical trial. More than 90% of patients began the drug within three months of stopping their previous cancer treatment. While further trials will be needed, the results offer hope for patients with few remaining options.